BiondVax to Present at Influenza 2018 Oxford Conference

Jerusalem, Israel – September 4, 2018 –BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford.Joshua Phillipson, BiondVax’s Business Development Manager, will provide an overview of the Company’s clinical development achievements and plans, including the recently launched pivotal, clinical efficacy, Phase 3 trial.Details of Mr. Phillipson’s talk:Getting Closer to the Market: M-001 Universal Flu Vaccine Starting Pivotal Phase 3 TrialDate: Wednesday, September 5, 2018Time: 10:40amLocation: Vernon Harcourt Room, South Building, St Hilda’s College, University of Oxford, UK.About BiondVaxBiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit www.biondvax.com.